title: [Role of PET/CT in diagnosis and treatment of breast cancer -- review of present knowledge and perspectives for future research].
abstract: Positron emission tomography (PET) has revolutionized the diagnostic opportunities of malignances, however, it has still a controversial role at some conditions in the management of breast cancer. The article compares PET alone and PET/CT. We review the latest trends of using PET or PET/CT for diagnosis, staging, evaluation of the primary tumor and regional lymph node status, as well as early detection of recurrence and distant lesions. PET/CT provides new methods of assessment of early chemo/endocrine therapy response of locally advanced breast cancer. We discuss the development of new radiotracers and their value in predicting treatment response, identifying tumor subtypes and finding new therapeutic targets by them.
authors.affiliation: Országos Onkológiai Intézet, B-Belyógyászati, Onkológiai és Klinikai Farkológiai Osztály, Budapest, Hungary. madarasb@gmail.com
authors.forename: Balázs
authors.initials: B
authors.lastname: Madaras
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Horváth
authors.forename: István
authors.initials: I
authors.lastname: Láng
authors.forename: Miklós
authors.initials: M
authors.lastname: Kásler
authors.forename: Katalin
authors.initials: K
authors.lastname: Borbély
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008327:Mammography / Q000379:methods*; D064847:Multimodal Imaging / Q000379:methods / Q000592:standards; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals